

Role of therapeutic plasma exchange in oncology patients with acute liver failure at a tertiary care oncology centre



eP128

Abinash Padhy, Priti Desai, Anisha Navkudkar, Abhaykumar Gupta Department of Transfusion Medicine, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai

Background and Objectives


- Acute liver failure (ALF) in oncology patient poses significant challenges in patient management.
- Therapeutic plasma exchange (TPE) emerged as a bridging intervention.
- This study elucidate the outcomes of oncology patients with ALF treated with TPE.
- TPE performed on these patients as per ASFA recommendation.

Methods

- Study-Single centre retrospective observational study.
- Study Period 3 years (January 2021- December 2023).
- Data source Electronic medical records and Departmental records
- Parameters analysed ○ Demographic data
 - Procedure details
 - Underlying malignancies,
 - Pre and post procedure LFT and coagulation profile.
- Wilcoxon paired T test used to analyse the co-relation between the variables.

Results

- Total 12 TPE procedures were performed on 6 oncology patients (Table2).
- Out of 6 patients 50%(3) were Male and 50%(3) were females.
- Mean age 39 years (9-66 years)
- Mean of 2 (1-3) TPE sessions performed on alternate day.
- Average 1.25 times total plasma volume were exchanged per session with combination of O Albumin
 - Normal Saline
 - Fresh Frozen Plasma as per patients clinical requirement.
- Data showed improvement in LFT (Figure 1,4,5,6 & Table 1) and coagulation profile (Figure 2,3 & Table 1) in these set of patients post TPE.
- More than 30 days survival was observed in 50% of the patients under study.







Pre TPE


Post TPE

P value

DT	Mean (SD)	40 (45)	17.2 (7.3)	0.023		
PT (Seconds)	Median (IQR)	22 (14, 41)	17.3 (13.4, 22.9)			
<u> </u>	Range	11, 169	1.0, 27.0			
	Mean (SD)	3.40 (4.01)	2.47 (3.49)	0.289		
INR	Median (IQR)	1.79 (1.18, 3.13)	1.79 (1.18, 3.13) 1.52 (1.18, 1.83)			
	Range	0.96, 14.86	0.99, 13.50			
	Mean (SD)	80 (78)	41 (15)			
aPTT (Seconds)	Median (IQR)	46 (38, 69)	37 (30, 47)	0.136		
(00001100)	Range	29, 247	29, 79			
ALT	Mean (SD)	1,179 (1,148)	464 (497)			
ALT (U/L)	Median (IQR)	1,005 (228, 1,541)	329 (120, 567)	0.005		
,	Range	35, 3,901	41, 1,731			
ACT	Mean (SD)	2,338 (2,230)	1,065 (1,255)			
AST (U/L)	Median (IQR)	2,248 (238, 3,444)	648 (110, 1,255)	0.005		
	Range	75, 6,875	71, 3,968			
ALD	Mean (SD)	127 (76)	99 (52)			
ALP (U/L)	Median (IQR)	96 (63, 180)	83 (60, 116)	0.034		
(- <i>i</i> - <i>i</i>	Range	54, 272	48, 208			
B.11: 1.1	Mean (SD)	24 (17)	18 (12)			
Bilirubin (mg/dL)	Median (IQR)	21 (13, 32)	14 (10, 24)	0.060		
()	Range	2, 58	4, 46			










Figure 5- Pre and post TPE AST

Figure 6- Pre and post TPE ALP

Table 2- Patient Demography

imary Diagnosis	Times TPVE	TPVE(mL)	TPV(mL)	TBV(mL)	WEIGHT(Kg)	GENDER	AGE(Yr)	Patient ID
epatoblastoma	0.75	1721	2282	2975	35	F	9	Case 1
HBV-CLD	1.5	3770	2467	3500	50	М	60	Case 2
atocellular Cancer	1.15	3787	3275	4130	59	М	30	Case 3
Ca Rectum	1.3	3258	2544	3640	56	F	25	Case 4
a Endometrium	1.85	4763	2590	3250	50	F	44	Case 5
Ca Esophagus	1.25	4201	3330	4970	71	М	66	Case 6

TBV- Total Blood Volume, **TPV-** Total Plasma Volume, **TPVE-** Total Plasma Volume Exchanged.

Conclusions

- TPE is well tolerated and safe procedure.
- It can be considered as a bridging therapy in oncology patients with ALF.

References

- 1.Therapeutic plasma exchange in acute liver failure. <u>Klaus Stahl, Johannes Hadem, Andrea Schneider, Michael P. Manns, Olaf Wiesner, Bernhard M. W. Schmidt, Marius M. Hoeper, Markus Busch, Sascha David https://doi.org/10.1002/jca.21737</u>
- 2. https://onlinelibrary.wiley.com/authored-by/Wiesner/Olaf https://doi.org/10.1002/jca.21799